MK-4716 Clinical Trials (2026): 1 Studies for Malignant Neoplasm
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 MK-4716 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Malignant Neoplasm) and 250 total planned enrollment. 1 MK-4716 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07247110 (Dec 2030).
Where to Participate: All MK-4716 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting MK-4716trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NJ | Rutgers Cancer Institute of New Jersey ( Site 0052) | New Brunswick08903 | NCT07247110 | Map |
| TX | NEXT Oncology ( Site 0051) | Irving75039 | NCT07247110 | Map |
| VA | NEXT Virginia ( Site 0054) | Fairfax22031 | NCT07247110 | Map |
MK-4716 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting MK-4716 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07247110 | MK-4716-001A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | P1 | Malignant Neoplasm | 250 | Dec 2025 |
All MK-4716 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07247110 | MK-4716-001 | A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | P1 | recruiting | 250 | Merck Sharp & Dohme LLC | Dec 2025 |
MK-4716 clinical trials: frequently asked questions
- How many MK-4716 clinical trials are there?
- 1 MK-4716 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are MK-4716 clinical trials recruiting in 2026?
- Yes — 1 MK-4716 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is MK-4716 being studied for?
- MK-4716 is being studied for Malignant Neoplasm. The trials are grouped by indication on this page.
- What phase is MK-4716 in?
- MK-4716 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MK-4716 clinical trials?
- The lead sponsor across the most MK-4716 trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MK-4716as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: